TSE:MSL Merus Labs International (MSL) Stock Price, News & Analysis → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free MSL Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$1.65▼C$1.6552-Week Range N/AVolume21,975 shsAverage Volume476,228 shsMarket CapitalizationC$193.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Merus Labs International alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Merus Labs International Stock (TSE:MSL)Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. MSL Stock News HeadlinesMay 15, 2024 | americanbankingnews.comMerus Labs International (TSE:MSL) Share Price Passes Above Two Hundred Day Moving Average of $0.00January 10, 2024 | ca.finance.yahoo.comAlbert Labs International Corp. (ABRT.CN)September 1, 2023 | finance.yahoo.comDefense Technologies International Corp. (DTII) Expands and Signs PT Lab Sistematika Indonesia as Distributor for SOUTHEAST ASIAMarch 19, 2023 | newsweek.comGlobal Biosafety Fears Grow Amid Rise in Labs Handling Dangerous PathogensFebruary 22, 2023 | finance.yahoo.comLaboratory Information System Global Market Report 2023February 19, 2023 | chicago.suntimes.comPalatine shocks Rolling Meadows, wins MSL title for the first time in 30 yearsJanuary 3, 2023 | finance.yahoo.comVeterinary Reference Laboratory Global Market Report 2022: Ukraine-Russia War ImpactOctober 15, 2022 | markets.businessinsider.com4 Analysts Have This to Say About MerusSeptember 18, 2022 | investing.comAlbert Labs International Corp (ABRT)August 29, 2021 | msn.comFootball World Reacts To Bizarre Situation On ESPNAugust 27, 2021 | msn.comGirls Soccer: Worthington Christian Warriors plan to make strides under new coachAugust 25, 2021 | msn.comMSL and aizy spearhead new Danish CS:GO lineupAugust 17, 2021 | msn.comHow to unlock a Boost Mobile phone and use it with other carriersAugust 12, 2021 | msn.comRoundup: Lancaster golfers place third in OCC; BC boys win MSL tourneySee More Headlines Receive MSL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus Labs International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/19/2024Next Earnings (Estimated)8/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorFinance Industry Major Banks Sub-IndustryN/A Current SymbolTSE:MSL CUSIPN/A CIKN/A Webwww.meruslabs.com Phone+1-905-7260995FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares117,355,000Free FloatN/AMarket CapC$193.64 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMichael S. CloutierIndependent Chairman of the BoardBarry FishmanChief Executive Officer, DirectorMichael Scott BumbyChief Financial OfficerRobert McLayVice President - Sales and MarketingFrank RotmannVice President and Head of European OperationsRobert Bloch M.D.DirectorTheresa Sheila FirestoneIndependent DirectorDavid D. Guebert CPAIndependent DirectorRobert S. PollockIndependent DirectorTimothy G. SorensenIndependent DirectorMore ExecutivesKey CompetitorsBMO Equal Weight US Banks Index ETFTSE:ZBKCanso Credit Trust - Canso Credit Income FundTSE:PBY.UNTemple HotelsTSE:TPH8002 (PIH.TO)TSE:PIHFounders Advantage Capital Corp. (FCF.V)CVE:FCFView All Competitors MSL Stock Analysis - Frequently Asked Questions Should I buy or sell Merus Labs International stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merus Labs International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MSL shares. View MSL analyst ratings or view top-rated stocks. When is Merus Labs International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 26th 2024. View our MSL earnings forecast. How were Merus Labs International's earnings last quarter? Merus Labs International Inc. (TSE:MSL) posted its earnings results on Tuesday, May, 14th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. Is Merus Labs International a good dividend stock? Merus Labs International (TSE:MSL) pays an annual dividend of C$0.04 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Merus Labs International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus Labs International investors own include Aurora Cannabis (ACB), (MSLI) (MSLI), ProMetic Life Sciences (PLI), GuestLogix (GXI), Royal Bank of Canada (RY), Sierra Wireless (SWIR), Village Farms International (VFF) and Wheaton Precious Metals (WPM). How do I buy shares of Merus Labs International? Shares of MSL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:MSL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Labs International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.